Juvenescence raises another $100m to invest in technology designed to cheat death

The fountain of eternal youth could come in technological form thanks to $100 million investment in a life sciences company. Juvenescence is working with drug developers and AI experts to create treatments and technologies to treat age-related diseases and to increase human longevity. The firm, set up by London City of London entrepreneur Michael Spencer, announced a total investment of $10 million from its founders. A further $10 million each will come from four cornerstone investors, including Grok Ventures, Mike Cannon-Brookes and Mr Spencer's private investment company. This brings the total to $165 Million that Juvenescence has raised in 18 months.